Government agency Health Innovation Hub has signed an agreement to fast-track the introduction of Pacific Edge’s non-invasive bladder cancer detection system to the four main district health boards.
The agreement effectively means that 2.2 million New Zealanders (half the population) now have faster access to Pacific Edge’s Cxbladder technology.
The company says this will result in significant savings to DHBs from using Cxbladder as an alternative to commonly used testing regimes.
Pacific Edge chief executive David Darling says the agreement is a strong endorsement of the company’s ability to deliver sound clinical outcomes for patients and “significant savings in time and expense” for DHBs.
“The option of patients being able to give a urine sample at home and for clinicians to receive the results a few days later has the potential to offer DHBs significant cost benefits by reducing the number of patients requiring a full clinical work-up.”
The HIH is a recently formed government enterprise with a mandate to enable technology commercialisation into and out of the country’s four largest DHBs.
HIH chief executive Frances Guyett says identifying and forming strategic relationships with key external partners to accelerate commercialisation by enabling access to DHBs is one of the HIH’s key objectives.
“Cxbladder is an exciting innovation, with the potential to bring benefits to millions of people who show the symptoms of or need monitoring for bladder cancer.”
Meanwhile, Cxbladder has recently also completed a "blinded user program" in both Waitemata and Canterbury DHBs.
“It was particularly pleasing to see such great results from these blinded studies, confirming the outcome of the large clinical study published in the Journal of Urology in the US in September 2012,” Mr Darling says.
Pacific Edge’s stated goal is for $100 million annual revenue within the next five years.
The shares [PEB:NZX] are up 8c (4.9%) to $1.72 on the news.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Serco's prison report challenge: Hide and Davis go head-to-head
- Tech expert's complaint about 'snake oil' ad upheld
- iPredict closing down due to money laundering risk
- Xero directors Drury, Winkler and Morgan cash in on 35% share price rally
- Dunne warns of 'consequences' if Maori Party supports RMA reform
Most listened to
- “A very ballsy thing to do” – Rodney Hide and Kelvin Davis discuss Serco’s response to Correction’s Mt Eden Prison report
- “The response from shareholders has been overwhelming” — A2 Corporation chief executive Geoff Babidge
- Greg Gent says a board of 13 people is "prehistoric"
- Arvida CEO Bill McDonald on his company's half-year net profit
- Lance Wiggs on the future of food exports
- Auckland Councillor Chris Darby on the Council's alternative funding report
- Nevil Gibson discusses his latest Editor's Insight on oil prices
- Campbell Gibson, Nick Grant and Chelsea Armitage chat about the inner workings of New Zealand media
- Paul Brislen discusses the 'snake oil' sales tactics of SalesConcepts
- Fonterra chief executive Theo Spierings reveals his ambitious China plan
- UDC Finance chief executive Wayne Percival talks about the company's profit
- Hamish McNicol discusses the latest court stories